Results From a 12-Month Open-Label Phase 1/2 Study of Velaglucerase Alfa in Children and Adolescents With Type 3 Gaucher Disease

AUTOR(ES)

Tantawy, Azza A. G.

FONTE

J. inborn errors metab. screen.

DATA DE PUBLICAÇÃO

28/02/2019

RESUMO

Abstract Gaucher disease (GD) is an autosomal recessive lipid storage disorder, caused by deficient activity of the lysosomal enzyme b-glucocerebrosidase, resulting in accumulation of glucocerebroside in tissue macrophages. HGT-GCB-068 was an open-label study designed to explore the efficacy and safety of velaglucerase alfa in children and adolescents with type 3 GD, a neuronopathic form of the disease. Six treatment-naive patients received infusions of velaglucerase alfa every other week at 60 U/kg over 12 months. Velaglucerase alfa demonstrated a favorable tolerability profile, and 1 infusion-related reaction (headache) was the only drug-related adverse event reported. Numerical increases from baseline in hematological parameters and decreases in visceral parameters were seen at 12 months. http://ClinicalTrials.gov identifier NCT01685216.

Documentos Relacionados

• Active music therapy in dementia: results from an open-label trial
• Occupational therapy in spinocerebellar ataxia type 3: an open-label trial
• Occupational therapy in spinocerebellar ataxia type 3: an open-label trial
• Paroxetine in Patients With Irritable Bowel Syndrome: A Pilot Open-Label Study
• Immunogenicity and safety of Southern Hemisphere inactivated quadrivalent influenza vaccine: a Phase III, open-label study of adults in Brazil